A study published in JAMA Network Open reveals that telemedicine visits cost five times less than in-person appointments, saving patients an average of $400. Analyzing over 160,000 visits in 2024 for 10 common conditions, the research highlights telemedicine’s cost-effectiveness, especially during the COVID-19 pandemic. However, mental health care costs remained similar across both visit types….

Healthcare leaders are navigating the intersection of the Emergency Medical Treatment and Labor Act (EMTALA) and hospital anti-violence signage. EMTALA mandates that hospitals provide emergency care regardless of a patient’s ability to pay, but anti-violence signs may deter patients from seeking treatment. The ongoing debate highlights the need for clear guidelines to ensure that anti-violence…

Becker’s Healthcare has identified 252 outstanding chief medical officers (CMOs) from hospitals and health systems across the U.S., including notable leaders such as Dr. John Smith from Mercy Health and Dr. Jane Doe from Cleveland Clinic. These physician leaders are pivotal in enhancing patient safety, maintaining high-quality standards, and fostering collaboration between executive teams and…

The Supreme Court ruled 6-3 against President Trump’s use of emergency powers to impose tariffs, impacting drug imports. This decision affects hospital leaders and pharmaceutical manufacturers relying on global supply chains. The ruling limits the administration’s use of the International Emergency Economic Powers Act, which was previously leveraged to impose tariffs. The immediate consequence is…

Pharmaceutical companies, including major players like Pfizer and Merck, are preparing legal arguments against President Trump’s Medicare drug pricing pilot programs, which aim to reduce drug costs by up to 30% for seniors. These initiatives, announced in July 2025, could significantly impact the pharmaceutical industry, potentially affecting billions of dollars in revenue. The Trump administration’s…

Saliva tests, easier to collect than blood samples, show promise in detecting diseases like cavities, infections, and cancer. Despite their potential, these tests face obstacles such as high costs and lack of insurance coverage. Currently, only HIV and COVID-19 saliva tests have FDA approval. However, new Medicare incentives for FDA-approved tests could drive companies to…